Reuters
11 Sept 2026, 05:02 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Setbacks to drugs acquired through M&A have negatively impacted Novartis's share price. — Direct losses in value from failed or underperforming acquisitions signal poor capital allocation and immediate financial drag.
-0.60Investors are raising concerns regarding the quality and viability of the Novartis drug pipeline. — Pipeline uncertainty reduces long-term growth projections and increases the risk profile for pharmaceutical investors.
-0.40Investors are increasing scrutiny of the company's dealmaking and M&A strategy. — Higher scrutiny often leads to pressure for management changes or a more conservative, less growth-oriented spending approach.
-0.20Which stocks this story touches
Continue reading
5 related stories
Top 2 movers · tap to explore
The company is facing investor scrutiny and share price declines due to setbacks in its M&A-acquired drug pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
3h ago
